Interim report

January - March, 2022

A Swedish group in the biotechnology sector focused on development and sales of products and services within animal health

INTERVACC

A new generation of vaccines within animal health

The period in summary

First quarter January 1 – March 31, 2022

- On March 23 the first batch of Strangvac® was released for sale in Sweden.
- Intervacc has applied for supplementary protection certificates (SPCs) for Strangvac® in key European markets. SPCs are an intellectual property right that serves as an extension to a patent right.
- EMA extended the shelf life of the antigens used in Strangvac® to 28 months.
- During February an application for a Permit for Sale and Distribution of Strangvac® in the U.S. was submitted to the U.S. Department of Agriculture (USDA).
- New study confirmed that Strangvac® is likely to be effective against all known strains of *Streptococcus equi*.

Figures in brackets indicate outcome for the corresponding period of the previous financial year. The financial information presented relates to the Group unless otherwise stated.

Table of Contents



CEO Comments

Sales of Strangvac® have started!

On March 23rd, Strangvac® was released for sale onto the Swedish market and the following week, the first pharmacies began placing orders and taking deliveries of the vaccine. The first horses in Sweden have been vaccinated and we look forward to working with Dechra to launch Strangvac® across Europe.

In the period between approval and the start of sales, we have taken part in meetings and discussions that has reached over a hundred Key Opinion Leaders (KOL's) across Europe. As Strangvac® is made available for sale in each specific market, we will initiate local training activities to a broader group of veterinarians and at the same time we will use information campaigns to raise the awareness of horse owners to equine strangles and how they can prevent this disease. In Sweden, we are now in this second phase, and we have seen several examples of leading KOL's independently supporting the vaccination of horses with Strangvac®. Strangvac® is a new, innovative vaccine and it is natural that questions arise during this phase. Many veterinarians choose to seek more knowledge by contacting us or by reading published studies about Strangvac®. We have great faith in Strangvac® and its value to prevent strangles in horses around the world.

We are also making ourselves available to discuss strangles and will, for example, be present at the Falsterbo Horse Show and at the FEI World Championships in Herning Denmark later this summer. We continue to support established campaigns that highlight equine strangles such as Strangles Awareness Week. This campaign has already reached millions of horse owners throughout the world. In addition we and Dechra are launching new initiatives. In Sweden, we have launched the campaign "Tillsammans mot kvarka", that translates to "Together against equine strangles". The purpose is to highlight equine strangles and the solutions and tools that are available. One of these important tools is vaccination.

Strangvac® is centrally approved for sale throughout the EU and in the UK, Norway, and Iceland. We have manufactured vaccines for the launch phase in Europe and expect to be able to start sales in several European countries in the coming weeks. We are well prepared to launch together with Dechra, which is one of the world's largest veterinary pharmaceutical companies and one of Europe's foremost distributors of medicines for horses.

The number of horses in Europe that are currently part of a vaccination program varies greatly between regions. In the Nordic countries, Germany and France, the vaccination rate against equine influenza is estimated to be over 70%, while in the United Kingdom in a normal year it is estimated to be between 40% and 50%. In southern Europe, the vaccination rate is usually lower.

There are an estimated 60 million horses in the world. About a third, i.e., about 20 million of these horses are in what we define as our primary markets, which includes Europe and North America. Our goal is for half of these 20 million horses to be included in a vaccination program where they are vaccinated against equine strangles. Feedback from KOLs and equine veterinarians found that for the majority of horses, the vaccination interval for Strangvac® will in practice be adapted to fit alongside established vaccination programs such as those against equine influenza. For equine influenza, after the horse has been vaccinated with two or three doses at the beginning of the vaccination program, they are re-vaccinated once or twice a year. In countries where vaccination against equine influenza is common, such as in Sweden, outbreaks of equine strangles are normally ten to twenty times more prevalent than outbreaks of equine influenza. The hopes and expectations of several leading equine veterinarians are that with vaccination against equine strangles, and by continuing to use other traditional infection control measures, we can reduce the number of equine strangles outbreaks to the same low level as the number of influenza outbreaks.

We expect that horses that start a vaccination program will continue to be vaccinated continuously for many years, often for life, and that once we have established the use of Strangvac® in a market, its use will continue to grow as the vaccine and its benefits become better known among horse owners, veterinarians, organizations, and other stakeholders such as insurance companies. The establishment of a new vaccine usually follows a traditional S-curve, with an introductory phase, an expansion phase, and a maturation phase where the maturation phase involves an established position with continued growth at a slower pace. How long it takes from launch to maturation phase differs greatly between different products. For biological pharmaceuticals, it is common for the time interval between launch and maturation phase to be 3–8 years.

On April 25, we issued a press release in which we spoke about the very promising results we have received in our project to develop a vaccine against *Streptococcus suis*. The study showed that piglets from sows vaccinated with our prototype vaccine had significantly fewer clinical signs of disease, compared to piglets from sows given a placebo vaccine, after experimental infection with *S. suis* at 4 or 7 weeks of age (one group of piglets underwent infection at 4 weeks of age and another group at 7 weeks of age). Protecting piglets by vaccinating the sow is both practical and cost-effective. We believe that we have taken a large and important step towards developing an attractive vaccine against a disease that is highlighted as a serious problem to the pig industry. The availability of an effective vaccine is particularly important as society seeks to reduce the use of antibiotics in food-producing animals. There is currently no effective vaccine approved for use against *S. suis*. Therefore, a cost-effective, practical and safe vaccine is urgently sought and has potentially a very high value. Although there is still development work left to do, we believe that our chances of success have increased significantly. Our results within the *S. suis* project have also made it possible for us to apply for additional patents which, if granted, complement our patent for a vaccine against *S. suis* which was already granted in the USA at the end of 2021 and which is under application in the EU.

We have also made good progress in our project to develop a vaccine against infections caused by *Staphylococcus aureus*. In our recently completed study, we showed that our prototype vaccine was safe and immunogenic in pregnant heifers. In our next phase, which will be partly funded by the EU's VetBioNet initiative, we will conduct a proof-of-concept study to measure the effectiveness of the vaccine in heifers. Our primary goal is to show that vaccinating dairy cows

against *Staphylococcus aureus* infections, can reduce the severity and prevalence of this type of mastitis in the dairy industry.

We see the success of Strangvac® and our development projects as a confirmation of the potential of our technology platform. We have shown that we can develop vaccines against bacterial diseases for which it has so far been difficult to develop effective vaccines. We have also shown that we can independently take such a vaccine from development, through the production and regulatory processes to become a commercial product. Our assessment is that the need for vaccines against bacterial infectious diseases will continue to increase and our position is strong.

Vaccination is one of the prerequisites for a sustainable and resilient society with reduced antibiotic use and healthier animals.

We fight infectious diseases best together. We start with equine strangles.

Together against equine strangles.

Follow our news on the website and via our twitter feed @intervacc_se

Andreas Andersson, CEO

Financial Summary

Group

Net Sales

Net sales during the first quarter of 2022 amounted to SEK 1.2 million, which is on a par with the same period 2021 (1.1). The company's first proprietary product, Strangvac®, began to be sold on the Swedish market in the last days of March 2022. Together with our partner and distributor Dechra Pharmaceuticals, Strangvac® will now, as it becomes possible, be launched on other markets in Europe where we are market authorization holder.

Earnings

Operating result for first quarter of 2022 amounted to SEK -10.7 million, which is 4.2 million worse compared to the same period in 2021 (-6.5). The negative operating result is mainly explained by the fact that the Group's first proprietary product, Strangvac, began to be sold on the Swedish market in the last days of March 2022 and that the company does not yet generate sufficient funds from its own business to finance its operations. The deterioration compared with the previous year is mainly explained by the fact that the Group has strengthened the organization, has continued the development of the projects in the pipeline, and has with the launch of Strangvac® begun depreciation of capitalized development costs.

Cash Flow

During the first quarter of 2022, working capital increased by and affected cash flow by SEK -10.5 million (+18.3), mainly through the build-up of inventories, which meant that SEK -8.4 million (+9.7) affected cash flow. Cash flow during the first quarter of 2022 has meant that cash and cash equivalents decreased by SEK -21.7 million (-15.3) and amounted to SEK 94 million (149) on the balance sheet date.

Financial position

At the end of first quarter 2022 equity amounted to SEK 297.5 million, which compared to the same date last year is a decrease with SEK 33.6 million. Approx. 54% (45%) of the group's total assets has been invested in capitalized expenditure which amounts to SEK 171.3 million (149.3). Cash which on the balance sheet date amounted to SEK 94 million (149), are greatly affected by the investments made in research and development, where our new and ongoing projects are becoming increasingly important. It also includes, for example, the upcoming regulatory process with the USDA (US Department of Agriculture), and technology transfer for the US market. The company is well equipped for continued commercialization and vaccine development.

Financial Summary continued

Parent company

Sales during the first quarter of 2022 in the parent company of SEK 3.7 million (-) refer to revenues from the company's first proprietary product, Strangvac®, which began to be sold on the Swedish market in March 2022. The negative operating profit is mainly explained by the company's first proprietary product, Strangvac®, began to be sold on the Swedish market in the last days of March 2022 and that the company is not yet generating sufficient funds from its own business to finance the operations. The deterioration compared with the previous year is mainly explained by the fact that the company has strengthened the organization, has continued the development of the projects in the pipeline portfolio and has with the launch of Strangvac® begun depreciation of capitalized development costs. On the balance sheet date 2022, equity amounted to SEK 325 million (350.3) and cash and cash equivalents to SEK 92.5 million (147.6).

Group key ratios

	2022-01-01 -2022-03-31	2021-01-01 -2021-03-31	2021-01-01 -2021-12-31
Net sales	1 172	1 116	5 241
Operating result	-10 697	-6 452	-29 393
Result after financial items	-10 726	-6 478	-29 375
Balance sheet total	316 263	343 973	329 393
Equity ratio	94%	96%	94%
Number of shares outstanding end of period	50 160 388	50 160 388	50 160 388
Average number of shares before dilution	50 160 388	50 160 388	50 160 388
Average number of shares after dilution	50 360 045	50 396 674	50 404 133
Earnings per share before dilution	-0,21	-0,13	-0,59
Earnings per share after dilution	-0,21	-0,13	-0,59

Significant events during the period January 1 – March 31, 2022

Strangvac®, a vaccine against equine Strangles, released for sale in Sweden

Intervacc announced on March 23 that the first batch of Strangvac® was released for sale onto the Sweden market. The product was in stock at our logistics partner in Sweden and after product information is registered in the system used by pharmacies around the country, the first pharmacies were able to place orders the following week and have the vaccine delivered.

Since Strangvac® was granted a marketing authorization by the European Commission in August 2021 we have taken part in meetings and discussions with over 200 KOL's Key Opinion Leaders (KOL's) and other equine veterinarians across Europe. With Strangvac® becoming available for sale, the next phase began with meeting and training veterinarians around Sweden to inform about Strangvac®. The interest has been great and our team has already met many veterinarians and completed training. Strangvac® has been launched in Sweden and we will now gradually launch in the rest of the Nordic region and Europe.

In parallel with the training of veterinarians, we have launched the campaign "Tillsammans mot kvarka", that translates to "Together against equine strangles". The purpose is to highlight equine strangles and the solutions and tools that are available. We are fully dedicated to the task of reducing the spread and effects of equine strangles. With information and knowledge, we can together protect our horses!

Intervacc applies for a Permit for Sale and Distribution of Strangvac® in the U.S.

On February 16th Intervacc announced that the Company's application for a Permit for Sale and Distribution of Strangvac® in the U.S. has been submitted to the U.S. Department of Agriculture (USDA).

New study confirms that Strangvac® is likely to be effective against all known strains of Streptococcus equi

In the largest study of its kind, published in the 'Equine Veterinary Journal', scientists confirm that the antigens used in the Strangvac vaccine were highly conserved regardless of which strain of *Streptococcus equi* was examined from outbreaks in 19 countries around the world.

Intervacc has applied for supplementary protection certificates for Strangvac® in key European markets

The European patent for Strangvac®, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection certificates, the protection in Great Britain, Sweden, the Netherlands, Italy, Ireland, France, Spain, Germany and Austria will be extended until May 2036.

Supplementary protection certificates (SPCs) are an intellectual property right that serves as an extension of the monopoly conferred by a patent, however limited to the specific pharmaceutical authorised by regulatory authorities and protected by the patent. The EU wishes to provide

sufficient protection for these products in the interest of public health and to encourage innovation.

Supplementary protection certificates aim to offset the loss of patent protection for pharmaceutical products that occurs due to the compulsory lengthy testing and clinical trials required prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years. Until the reporting date, Italy and the Netherlands have approved the application for additional protection for Strangvac®.

The European Medicines Agency extends the shelf life of the antigens used in Strangvac to 28 months

The European Medicines Agency has, after reviewing stability data, approved the extension of the shelf life of the antigens in Strangvac to 28 months.

The manufacturing of Strangvac®, a vaccine against the highly contagious equine disease strangles, takes place in two steps – first the antigens are produced in a process that yields sufficient antigens for several million doses, then vaccine doses are produced by mixing the antigens with adjuvant and saline. The reconstituted vaccine doses are transferred into vials that are labelled and packaged for sale. The antigens produced in step one can now be used for mixing with adjuvant and saline based upon the new extended shelf life of 28 months from the time of manufacture. The shelf life of the labelled vaccine doses in vials then has a further approved shelf life of 24 months, which is not limited by the shelf life of the antigens.

Significant events after the period

Positive results in proof-of-concept study to develop a vaccine against Streptococcus suis infection in pigs

On April 25 we announced positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with *Streptococcus suis*.

The study showed that piglets from sows that had been vaccinated with a prototype fusion protein vaccine had significantly fewer clinical signs of disease compared to piglets from sows that received a placebo, adjuvant-only, vaccine following challenge with a virulent strain of *Streptococcus suis* at 4 or 7 weeks of age.

Intervacc progresses vaccine to prevent mastitis in dairy cows caused by *Staphylococcus aureus*

Intervacc initiate a proof-of-concept study to measure the effectiveness of a vaccine to protect dairy cows against mastitis caused by *Staphylococcus aureus* following successful safety and immunogenicity studies testing this prototype vaccine in pregnant heifers. This next phase of the project will be receiving a grant of 80k Euro from the EU's VetBioNet initiative.

Mastitis is one of the most important diseases of dairy cattle worldwide. Over 2.6 million cases of disease, causing losses of approximately 600M€, occur in European farms each year. Approximately 25% of contagious mastitis cases are caused by *Staphylococcus aureus* and the control of mastitis is the most common reason for antibiotic use in dairy cows.

Shareholdings and the share

Shareholdings in Intervacc as of March 31, 2022:

Owner	Number of shares	% of cap/votes
Handelsbanken Microcap	4 315 000	8,6%
Robur	3 419 868	6,8%
Fjärde AP-fonden	2 450 000	4,9%
B. Sjöstrand incl. company	1 251 242	2,5%
K Janzon incl. Company	1 012 000	2,0%
H. Isoz	985 000	2,0%
Capital Group Smallcap World Fund	870 186	1,7%
N. Aguiar	855 761	1,7%
Aktia Asset Management Oy	800 000	1,6%
T. Eklund	780 887	1,6%
Nordea Småbolagsfonder	735 957	1,5%
NR Bergman incl. company	708 505	1,4%
Jyske Bank/Bank of NY	655 179	1,3%
Aktie-Ansvar Sverige	650 000	1,3%
BNP Paribas, Luxembourg	616 031	1,2%
Others	30 054 772	59,9%
Total no shares	**50 160 388**	100,0%

Changes in number of shares from January 1st 2020 until balance sheet date is presented in the table below.

		Number of shares		Share capital, SEK	
	Price	Increase	Total	Increase	Total
Values 2020-01-01			43 292 690		86 585 386
May 2020, incentive program 2017/2020:1	9,09	271 200	43 563 890	542 400	87 127 786
May 2020, incentive program 2017/2020:2	9,09	22 600	43 586 490	45 200	87 172 986
June, 2020, directed share issue	22,50	6 537 973	50 124 463	13 075 947	100 248 933
July 2020, incentive program 2017/2020:1	9,09	10 500	50 134 963	21 000	100 269 933
July 2020, incentive program 2017/2020:2	9,09	25 425	50 160 388	50 850	100 320 783

The company's share is listed on Nasdaq First North Growth Market and traded with the tickername "IVACC". The shares have a quota value of 2,00 SEK. The graph below shows the Intervacc share's closing prices from January 1st, 2019 to May 10th, 2022

The Group

CONSOLIDATED INCOME STATEMENT IN SUMMARY

	2022-01-01 -2022-03-31	2021-01-01 -2021-03-31	2021-01-01 -2021-12-31
Operating income			
Net sales	1 172	1 116	5 241
Work performed by the company for its own use and	953	1 020	3 682
Other operating income	448	547	2 516
Total operating income	2 573	2 683	11 439
Operating expenses			
Goods for resale, raw materials and consumables	-526	-715	-2 677
Other external costs	-4 703	-2 829	-14 651
Employee benefit expenses	-4 697	-3 941	-17 025
Depreciation/amortization of property, plant and equipment and intangible assets	-3 018	-1 541	-6 152
Other operating expenses	-326	-109	-327
Total operating expenses	-13 270	-9 135	-40 832
Operating loss	**-10 697**	**-6 452**	**-29 393**
Profit and loss from financial items			
Net financial items	-29	-26	18
Total financial items	-29	-26	18
Loss before tax	**-10 726**	**-6 478**	**-29 375**
Taxes			
Tax on profit	-	-	-
Net loss for the period	**-10 726**	**-6 478**	**-29 375**
Earnings per share before dilution attributable to the Parent Company's shareholders	-0,21	-0,13	-0,59
Earnings per share after dilution attributable to the Parent Company's shareholders	-0,21	-0,13	-0,59

The Group

CONSOLIDATED BALANCE SHEET IN SUMMARY

	2022-03-31	2021-03-31	2021-12-31
ASSETS			
Fixed Assets			
Capitalized expenditure for research and development and similar	172 264	153 637	171 259
Concessions, patents, licenses, trademarks and similar rights	8 461	7 868	8 064
Goodwill	10 313	16 206	11 786
Tangible assets	1 639	597	861
Financial assets	11 390	11 390	11 390
Total fixed assets	**204 067**	**189 698**	**203 360**
Current assets			
Inventories	15 054	1 401	6 613
Current receivables	3 144	3 896	3 708
Cash and bank balances	93 998	148 978	115 712
Total current assets	**112 196**	**154 275**	**126 033**
TOTAL ASSETS	**316 263**	**343 973**	**329 393**
EQUITY AND LIABILITIES			
Equity	297 524	331 127	308 252
Non-current liabilities	212	157	222
Current liabilities	18 527	12 689	20 919
TOTAL EQUITY AND LIABILITIES	**316 263**	**343 973**	**329 393**

The Group

CONSOLIDATED CASH FLOW STATEMENT IN SUMMARY

	2022-01-01 -2022-03-31	2021-01-01 -2021-03-31	2021-01-01 -2021-12-31
Cash flow from operating activities before working capital changes	**-7 490**	**-4 936**	**-23 206**
Cash Flow from changes in working capital			
Change in inventories	-8 441	183	-5 029
Change in receivables	344	-841	-647
Change in current liabilities	-2 375	-4 700	3 419
Cash flow from operating activities	**-17 962**	**-10 294**	**-25 463**
Investing activities			
Investment in capitalized expenditure for research and development, patents and similar	-2 844	-4 619	-22 437
Net investment in tangible assets	-881	-235	-690
Cash flow from investing activities	**-3 725**	**-4 854**	**-23 127**
Financing activities			
Borrowings	-	-	264
Repayment of debt	-27	-126	-214
Cash flow financing activities	**-27**	**-126**	**50**
Cash flow for the period	-21 714	-15 274	-48 540
Cash beginning of the period	115 712	164 252	164 252
Cash end of the period	**93 998**	**148 978**	**115 712**

Parent company

INCOME STATEMENT IN SUMMARY

	2022-01-01 -2022-03-31	2021-01-01 -2021-03-31	2021-01-01 -2021-12-31
Operating income			
Net sales	3 706	-	259
Work performed by the company for its own use and capitalized	953	1 020	3 682
Other operating income	444	534	2 467
Total operating income	5 103	1 554	6 408
Operating expenses			
Goods for resale, raw materials and consumables	-1 278	-	-
Other external costs	-4 424	-2 364	-12 824
Employee benefit expenses	-3 516	-2 790	-12 579
Depreciation/amortization of property, plant and equipment and intangible assets	-1 521	-17	-104
Other operating expenses	-298	-101	-281
Total operating expenses	-11 037	-5 272	-25 788
Operating loss	**-5 934**	**-3 718**	**-19 380**
Profit and loss from financial items			
Net financial items	-27	-1	53
Total financial items	-27	-1	53
Loss after financial items	**-5 961**	**-3 719**	**-19 327**
Appropriations			
Group contribution	-	-	-3 784
Loss before tax	**-5 961**	**-3 719**	**-23 111**
Taxes			
Tax on profit	-	-	-
Net loss for the period	**-5 961**	**-3 719**	**-23 111**

Parent company

BALANCE SHEET IN SUMMARY

	2022-03-31	2021-03-31	2021-12-31
ASSETS			
Fixed Assets			
Capitalized expenditure for research and development and similar	172 264	153 637	171 259
Concessions, patents, licenses, trademarks and similar rights	8 461	7 868	8 064
Tangible assets	1 466	325	665
Financial assets	45 599	45 599	47 118
Total fixed assets	**227 790**	**207 429**	**227 106**
Current assets			
Inventories	12 038	-	5 046
Current receivables	8 096	4 584	2 612
Cash and bank balances	92 499	147 637	113 877
Total current assets	**112 633**	**152 221**	**121 535**
TOTAL ASSETS	**340 423**	**359 650**	**348 641**
EQUITY AND LIABILITIES			
Equity	324 959	350 313	330 921
Non current liabilities	212	-	222
Current liabilities	15 252	9 337	17 498
TOTAL EQUITY AND LIABILITIES	**340 423**	**359 650**	**348 641**

Changes in Equity

	Group		
	Share capital	Other contributed capital	Other equity including result for the period
Equity by 2021-01-01	**100 321**	**287 688**	**-50 399**
Translation difference during period			-5
Net result during period			-6 478
Equity by 2021-03-31	**100 321**	**287 688**	**-56 882**
Equity by 2022-01-01	**100 321**	**287 688**	**-79 757**
Translation difference during period			-2
Net result during period			-10 726
Equity by 2022-03-31	**100 321**	**287 688**	**-90 485**

	Parent company					
	Share capital	Statutory reserve	Development expenditure reserve	Share premium reserve	Loss brought forward	Loss for the period
Equity by 2021-01-01	100 321	17	90 611	287 671	-105 480	-19 108
Provision to development			4 361		-4 361	
Transfer of the previous year's result					-19 108	19 108
Net result during period						-3 719
Equity by 2021-03-31	**100 321**	**17**	**94 972**	**287 671**	**-128 949**	**-3 719**
Equity by 2022-01-01	100 321	17	112 594	287 671	-146 571	-23 111
Provision to development expenditure reserve			1 004		-1 004	
Transfer of the previous year's result					-23 111	23 111
Net result during period						-5 961
Equity by 2022-03-31	**100 321**	**17**	**113 598**	**287 671**	**-170 687**	**-5 961**

Assessments, risks and uncertainty factors

In order to prepare reporting, the management and the Board must make assessments and assumptions that affect assets and liabilities, as well as income and expenses reported in the financial statements. The conditions for Intervacc's operations change gradually, which means that these assessments can change and affect both the company's position and profitability. The estimates and judgments in this section are those that are judged to be most important based on the significance of the assessments and the risks and uncertainties.

Strangvac®

Since only one of Intervacc's vaccine projects has reached a phase where it is possible to launch and can generate revenue, a significant part of the Company's assessed asset value can be attributed to the commercialization of this vaccine. This dependence means that there is a risk of a negative impact on the company's forecasts and asset value if any part of the launch of Strangvac® does not go as planned.

Financing

Research and development of pharmaceuticals is to a great extent a risky, complicated, time-consuming and capital-intensive process. The company has yet to approve in-house developed products and does not generate enough cash flow from its own business to finance its operations. There is a risk that financing cannot be secured for future capital needs or that such financing cannot be obtained on favourable terms, which can have negative effects on the company's survival, development and investment opportunities.

Key personnel

Intervacc is highly dependent on senior executives and other key personnel. Loss of key personnel can have negative financial and commercial effects on the company.

Sales and distribution

There is always a risk that the company or its partners will not achieve expected sales targets, which will result in lower revenues than projected. There is also a risk that Nordvacc's sales will not reach agreed minimum levels which may implicate that Nordvacc loses the right to be an exclusive sales representative.

Covid-19

The Covid-19 pandemic has also been in focus during 2021. How large and what the long-term effects of Covid-19 will be is still uncertain. It cannot be ruled out that it will have negative consequences for the company, such as shortcomings in the availability of medicines or materials for the manufacture of the company's products.

Intervacc in brief

Intervacc's business concept is to develop and sell its own vaccines against infections within animal health. The development of new vaccines is based on new technology using fused recombinant proteins that reduce the risk of serious side effects.

The group also includes Nordvacc Läkemedel AB, which distributes veterinary drugs in the Nordic and Baltic markets, and Mybac-Vettech AB, a laboratory that performs diagnostic services in veterinary bacteriology.

Strangvac®

Strangvac® is Intervacc's vaccine against the serious horse disease strangles. Clinical studies show the strength of the technology. The primary markets for the company are Europe and North America where the number of horses amounts to approximately 17 million (FAOSTAT). The company estimates that about 30-60% of all horses in these markets are vaccinated against various infectious diseases.

Other vaccine projects

In addition to Strangvac®, Intervacc is working on several vaccines, primarily a vaccine against infections caused by the bacterium *Streptococcus suis* that affects piglets and a vaccine against infections caused by the bacterium *Staphylococcus aureus* which affects dairy cows. Both projects are based on the same technology platform as Strangvac®.

Streptococcus suis causes sepsis and meningitis in pigs. The infection is one of the most common bacterial causes of fatal infection in weaned piglets and is a major health problem in the pig industry. Globally, there are about 1 billion pigs. *Streptococcus suis* is a zoonotic infection that also affects people.

Staphylococcus aureus is often the cause of mastitis (udder infection) in dairy cows. The infection leads to significant loss of production and is a major problem for the dairy industry. Globally, there are approximately 280 million dairy cows. *Staphylococcus aureus* infections are also a serious problem in humans, mainly in the form of MRSA *(methicillin-resistant staphylococcus aureus*).

Intervacc in brief, continued

Market

The veterinary drug market includes both food producing and companion animals. Globally, veterinary drugs have sales of approximately USD 40 billion and annual growth is forecasted at 4-6%. Growth is driven by increased demand for animal protein (including meat, fish, dairy products and eggs), technological advances, more pets, increased willingness to pay for pet treatments, increased awareness of the importance of animal health and the fight against antibiotic-resistant bacteria. Veterinary vaccine accounts for about 25-30% of the veterinary drug market and is expected to grow by about 6-10% annually.

There are about 60 million horses in the world. Our primary markets for Strangvac® are Europe (6 million horses) and North America (11 million horses).

Patents

Intervacc has an active patent strategy, which means that applications for patents and trademark protection are submitted in the countries that are considered to have good market potential or are considered to be key markets for the product in question. Continuous work is being done to ensure that we have so-called Freedom to Operate (FTO). An analysis for the company's vaccine Strangvac® for Europe and the United States confirms FTO.

The company currently owns 4 patent families. The patent families include a total of about 20 granted patents in different countries and a few further pending patent applications.

The four patent families are:

- Trivac, WO 2004/032957 A1, (priority year 2002).
  Patents are granted and in effect in the US.
- Penta/Septavacc, WO 2009/075646 A1, (priority year 2007).
  Patents are granted and in effect in Europe and in the U.S.
- Strangvac®, WO 2011/149419 A1 (priority year 2010)
  Patents are granted and in effect in Europe, in the U.S. (US 9,795,664), Hong Kong, China and Australia.
- *Streptococcus suis* vaccine, WO 2017/005913 A1 (priority year 2015)
  Patent granted in the U.S. (US 11,155,585) and application ongoing in Europe.

The main purpose of filed patent applications is to protect the company's products.

In addition, the applications also describe the possibility of developing vaccine products to protect against diseases caused by *Streptococcus zooepidemicus*. The application documents describe in detail the various vaccine components as well as development and application method.

Supplementary disclosures

Accounting policies

The Group and the Parent Company apply the Annual Accounts Act and BFNAR 2012: 1 Annual Report and Consolidated Accounts (K3). The accounting principles have remained unchanged since the most recent annual report. For a more detailed description of the accounting principles, see Intervacc AB (publ.) Annual Report for 2021, pages 31-34. All amounts are reported in TSEK unless otherwise stated.

Employee share-option plan

The Annual General Meeting of Intervacc resolved on June 11, 2019, on the issue of warrants and the introduction of a long-term incentive program (2019/2022) in the company aimed at senior executives and other key personnel. Each warrant entitles the holder to subscribe for a share in the company at a subscription price of SEK 18.52 during the period July 1, 2022 through December 30, 2022, which corresponds to 200 percent of the volume-weighted average price for the share in the company from June 12 to June 18, 2019. A total of 330 455 warrants have been assigned to senior executives.

During the first quarter of 2022, the average price of the company's share on Nasdaq First North Growth Market has exceeded the subscription price for options issued. The dilution effect corresponds to a dilution of 199 657 shares during the first quarter of 2022. This dilution effect should be compared to the number of shares issued at the balance sheet date amounting to 50 160 388 and the dilution corresponds to approximately 0,4% and has no effect on earnings per share.

Audit

This interim report has not been reviewed by the company's auditor.

This report has been prepared in a Swedish original version and translated into English. In the event of any inconsistency between the two versions, the Swedish language version should have precedence.

Stockholm May 20, 2022

Andreas Andersson
CEO

Certified adviser

Eminova Fondkommission is Intervacc's Certified Adviser.

Eminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
114 46 Stockholm
Tel: +46 8 684 211 10
adviser@eminova.se

Dates for upcoming reports

August 31, 2022	Interim report Q2 January 1 - June 30, 2022
November 10, 2022	Interim report Q3 January 1 - September 30, 2022
February 17, 2023	Year-end report January 1 - December 31, 2022

Annual General Meeting

Annual General Meeting 2022 will take place on June 14, 2022.

Contact information

Andreas Andersson, CEO
Tel: +46 (0)8 120 10 601
Mob: +46 (0)73 335 99 70
andreas.andersson@intervacc.se

The company's reports are published on the company's website www.intervacc.se/investors/reports.